Prophylactic Use of Low-Dose Interleukin-2 Early Post-Transplantation: a Randomised Study
Xiangyu Zhao,Xiaosu Zhao,Yutong Wang,Ying-Jun Chang,Lan-Ping Xu,Xiao-Hui Zhang,Yu Wang,Yu-Hong Chen,Wei Han,Huan Chen,Chen-Hua Yan,Feng-Rong Wang,Jing-Zhi Wang,Yu-Qian Sun,Fei-Fei Tang,Hai-Xia Fu,Kai-Yan Liu,Xiao-Jun Huang
DOI: https://doi.org/10.1016/s0140-6736(15)00585-1
2015-01-01
Abstract:BackgroundEvidence suggests that natural killer cells and regulatory CD4+CD25+FoxP3+ T (Treg) cells, which are expanded and stimulated by the application of interleukin-2, could mediate protection against graft-versus-host disease (GVHD) while maintaining graft anti-tumour activity. The aim of this study was to confirm that a low dose of interleukin-2 can prevent relapse while reducing chronic GVHD. This study has been presented in part as an oral presentation at the 56th American Society of Hematology Annual Meeting and Exposition (Dec 6, 2014) in San Francisco, CA, USA.MethodsIn this open-label, prospective, randomised controlled trial in a single centre in China, donor–recipient pairs were randomly assigned (1:1) into the interleukin-2 group and control group by the sub-investigator (treating physician of our transplant centre) according to a computer-generated randomisation system. We enrolled patients (aged ≥15 years) with standard-risk leukaemia (except Ph+ ALL and T-ALL) who had undergone unmanipulated allogeneic stem cell transplantation. The transplantation procedure for control group patients was the same as that of the interleukin-2 group, except for interleukin-2 treatment. Interleukin-2 treatment (daily 1×106 IU/m2 body-surface area) was repeated every 14 days for six courses until disease progression or unacceptable toxicity. The primary endpoint was the cumulative incidence of haematological relapse. The primary efficacy end point was a between-group comparison of the time from transplantation to relapse in the intention-to-treat population (all randomly assigned patients). 360 subjects were estimated to be needed to detect a 10% difference between groups in cumulative incidence of haematological relapse based on our previous results (from 20% to 10%) with a one-sided α of 0·05 and a power of 80%. Futility analyses after a quarter, half, and three-quarters of 360 cases were specified. This study was approved by the Institutional Review Board of Peking University, and written informed consent was obtained from all patients in accordance with the Declaration of Helsinki. This trial is registered with ClinicalTrials.gov, number NCT01517347.FindingsSince this study began in January, 2012, we have randomly assigned 43 patients to the interleukin-2 group and 47 patients to the control group. First interim analysis was done when 90 cases were enrolled. The cumulative incidence of haematological relapse of the interleukin-2 and control cohorts were 27% (95% CI 18–35%) and 9% (5–12%), respecitively; p=0·12). Low dose of interleukin-2 augmented reconstituted Treg cells and natural killer cells. The suppressive functions of interleukin-2-expanded Treg cells in inhibiting T-cell activation were comparable to healthy donors. Cytotoxicity of interleukin-2-expanded natural killer cells against K562 cells as well as against resting or activated conventional T cells (Tcon) was significantly enhanced compared to control group. Patients with severe chronic GVHD had a lower ratio of Treg to Tcon cells at 2 months and 3 months, and a lower ratio of CD56dim to CD56bri NK cells from 2 months to 5 months after allogeneic stem cell transplantation. Interleukin-2 therapy was well tolerated; the most common adverse event was fever.InterpretationLow dose of interleukin-2 given post-transplant did not decrease the cumulative incidence of haematological relapse and was associated with a higher frequency of an MRD-positive test and a lower frequency of chronic GVHD, which might be through expansion of Treg cells. Thus, the prophylactic application of interleukin-2 should be cautious and its effect on leukaemia relapse needs to be further explored.FundingThe National Natural Science Foundation of China, the Major State Basic Research Development Program of China, and Milstein Medical Asian American Partnership (MMAAP) Foundation Research Project Award in Hematology.